Company Overview:
Molecular Targeting Technologies, Inc. (MTTI) is a privately held biotechnology company focused on the development of diagnostic and therapeutic molecules to address the unmet medical needs in cancer and infection.
Mission:
We translate novel technologies into tomorrow's diagnostic and therapeutic solutions for cancer and infectious diseases.
Content on this page requires a newer version of Adobe Flash Player.
Brands/Product Lines
March 2011
Combining Lipophilic dye, in situ Hybridization, Immunohistochemistry, and Histology...see link
April 2011
Using small molecule probes for fluorescent imaging of apoptosis and bacterial infections in vitro and in vivo...read more
In Vivo Optical Imaging of Acute Cell Death Using a Near-Infrared
Fluorescent Zinc-Dipicolylamine Probe...read more
In Vivo Targeting of Cell Death Using a Synthetic Fluorescent
Molecular Probe...read more
Upcoming Tradeshows 2012
TBD
TBD
11 November 11
MTTI introduces CyAL-5 dye... read more
10 May 11
MTTI licenses robust NIR dye technology from Massachusetts General Hospital... read more
12 October 10
Jefferson Awarded Multi-Million Dollar NIH Grant for External Imaging of Cancer Gene Activity
... read more
22 September 10
Zn-DPA Cardiac Imaging Study presented by L. wyffels wins the Young Investigator Competition
.. read more
19 March 10
University Of Notre Dame and MTTI in Deal... read more
01 March 10
Molecular Targeting Technologies, Inc. Licenses Cell Targeting Technology from the University of Notre Dame... read more
Molecular Targeting Technologies Inc.
